Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $6.58

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)’s share price gapped up before the market opened on Friday . The stock had previously closed at $6.58, but opened at $6.85. Aurinia Pharmaceuticals shares last traded at $6.76, with a volume of 187,512 shares.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Monday, September 9th. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Trading Up 6.8 %

The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18. The business has a 50 day simple moving average of $6.06 and a two-hundred day simple moving average of $5.55. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -16.35 and a beta of 1.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. The business had revenue of $57.10 million during the quarter, compared to the consensus estimate of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. The business’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.08) earnings per share. As a group, equities analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.13 EPS for the current year.

Insider Activity

In related news, insider Scott Michael Habig sold 18,249 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total value of $96,902.19. Following the completion of the sale, the insider now directly owns 456,338 shares of the company’s stock, valued at $2,423,154.78. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of AUPH. HighMark Wealth Management LLC grew its holdings in shares of Aurinia Pharmaceuticals by 3.0% during the first quarter. HighMark Wealth Management LLC now owns 75,196 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 2,197 shares during the last quarter. ProShare Advisors LLC grew its stake in Aurinia Pharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock worth $173,000 after buying an additional 2,873 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in Aurinia Pharmaceuticals in the fourth quarter worth $30,000. Tidemark LLC acquired a new stake in Aurinia Pharmaceuticals in the fourth quarter worth $39,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Aurinia Pharmaceuticals by 10.0% during the second quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock valued at $301,000 after acquiring an additional 4,808 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.